trial · primary record
Capmatinib
Carcinoma, Non-Small-Cell Lung
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 57 |
| Primary completion | 2027-05-31 |
| Primary endpoint | Phase 1: Number of Participants with Adverse events (AEs) by Severity |
| Registry ID | NCT05488314 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:55:03.450Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT05488314
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.